The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Ching-Yi Chen  
E-Da Hospital

Chao-Hsien Chen  
Mackay Memorial Hospital

Cheng-Yi Wang  
Cardinal Tien Hospital

Chih-Cheng Lai  
Kaohsiung Veterans General Hospital Tainan Branch

Chien-Ming Chao  
Chi Mei Medical Center

Yu-Feng Wei (✉ yufeng528@gmail.com)  
Peking University School of Stomatology  https://orcid.org/0000-0002-6380-3527

Research

Keywords: Antibiotic, Antimicrobial agent, Co-trimoxazole, Doxycycline, Idiopathic pulmonary fibrosis, Outcome

DOI: https://doi.org/10.21203/rs.3.rs-696811/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

The effect of additional antimicrobial agents on the clinical outcomes of patients with idiopathic pulmonary fibrosis (IPF) is unclear.

Methods

We performed comprehensive searches of randomized control trials (RCTs) that compared the clinical efficacy of additional antimicrobial agents to those of placebo or usual care in the treatment of IPF patients. The primary outcome was all-cause mortality, and the secondary outcomes were changes in forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and the risk of adverse events (AEs).

Results

Four RCTs including a total of 1055 patients (528 receiving additional antibiotics and 527 receiving placebo or usual care) were enrolled in this meta-analysis. Among the study group, 402 and 126 patients received co-trimoxazole and doxycycline, respectively. The all-cause mortality rates were 15.0% (79/528) and 14.0% (74/527) in the patients who did and did not receive additional antibiotics, respectively (odds ratio [OR], 1.07; 95% confidence interval [CI], 0.76 to 1.51; p = 0.71). No significant difference was observed in the changes in FVC (mean difference [MD], 0.01; 95% CI, -0.03 to 0.05; p = 0.56) and DLCO (MD, 0.05; 95% CI, -0.17 to 0.28; p = 0.65). Additional use of antimicrobial agents was also associated with an increased risk of AEs (OR, 1.65; 95% CI, 1.19–2.27; p = 0.002), especially gastrointestinal disorders (OR, 1.54; 95% CI, 1.10–2.15; p = 0.001).

Conclusion

In patients with IPF, adding antimicrobial therapy to usual care did not improve mortality or lung function decline but increased gastrointestinal toxicity.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a devastating progressive interstitial lung disease without an identifiable etiology.[1] The prevalence of IPF is increasing worldwide, particularly in elderly populations.[2–5] Unlike other interstitial lung diseases, IPF is refractory to anti-inflammatory treatment with corticosteroids, and the prognosis is even worse than many cancers.[6] Therefore, IPF is associated with high morbidity and mortality, with a median survival of only 2–3 years from the time of diagnosis.[6] Large-scale randomized control trials (RCTs)[7, 8] have demonstrated that two anti-fibrotic agents, pirfenidone and nintedanib, can reduce the progression of IPF in lung function, exercise tolerance, and mortality. These two agents have obtained approval from the United States (US) Food and Drug Administration for the treatment of IPF and are widely used in the European Union (EU) and other countries worldwide. However, their usefulness may be limited by their high cost and difficult to tolerate toxicity.[9–11]

Due to the limited treatment options for this fatal condition, an effective low-cost treatment is urgently needed to improve the clinical outcomes of patients with IPF. A pilot study of co-trimoxazole (trimethoprim-sulfamethoxazole) in 20 patients with progressive fibrotic lung disease demonstrated that additional treatment with co-trimoxazole resulted in a significant improvement in shuttle walking test and lung function in terms of forced vital capacity (FVC).[12] In addition, in vitro studies have demonstrated that doxycycline and minocycline can improve pulmonary fibrosis by inhibiting growth factor and matrix metalloproteinase (MMP) production.[13, 14] Based on these promising findings, the effect of the additional use of antimicrobial agents such as doxycycline, co-trimoxazole, and macrolides on the outcomes of IPF patients have been assessed in further clinical studies.[15–17] Shulgina et al. reported a RCT of 181 IPF patients, and concluded that co-trimoxazole therapy could improve the quality of life and reduce mortality in those adhering to treatment.[18] In addition, a retrospective analysis of 209 IPF patients who received mechanical ventilation and high-dose corticosteroids showed that the concurrent use of co-trimoxazole (odds ratio [OR] = 0.28, 95% confidence interval [CI] 0.132–0.607; p = 0.001) and macrolides (OR = 0.37, 95% CI 0.155–0.867; p = 0.033) was significantly associated with reduced mortality.[15] Treating IPF with the addition of antimicrobial agents such as co-trimoxazole has also been shown to be cost-effective.[19] However, the findings of
subsequent large RCTs[20, 21] have been inconsistent. Therefore, we conducted this systematic review and meta-analysis of RCTs to investigate the effect of additional antimicrobial agents on the clinical outcomes of patients with IPF.

Methods

The study protocol was registered in the PROSPERO database with the ID number of CRD42021255619. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[22]

Study search and selection

We performed a comprehensive search of the PubMed, Embase, Web of Science and Cochrane Library databases from their inception to May 20th 2021. The following search terms were used: idiopathic pulmonary fibrosis and antibiotics (including co-trimoxazole, tetracycline, chlorotetracycline, oxytetracycline, demeclocycline, lymecycline, meclocycline, methacycline, metacycline, minocycline, rolitetracycline, doxycycline, tigecycline, eravacycline, sarecycline, omadacycline, azithromycin, clarithromycin, erythromycin, fidaxomicin). The clinical trials registries of ClinicalTrials.gov and WHO International Clinical Trials Registry Platform for relevant articles were also searched. The detailed search strategy is described in e-Table 1. Only RCTs that compared the clinical efficacy and safety of additional antimicrobial agents to those of placebo or usual care in the treatment of patients with IPF were included. The reference lists of relevant articles were also searched manually for additional eligible articles. No language limitations were applied.

Study selection and data extraction

Three investigators (CHC, CYC, CCL) independently screened and reviewed each study. Studies were included if they met the following criteria: (1) adult patients with IPF, (2) intervention of additional antimicrobial agents, (3) comparisons with placebo or usual care, (4) RCTs, and (5) efficacy outcome with or without safety. We excluded in vitro activity research, animal studies, and pharmacokinetic–pharmacodynamic assessments. If there were any disagreements, fourth and fifth investigators (CYW and FYW) were consulted. For each included study, we extracted the following data: year of publication, study design, antimicrobial regimens, clinical outcomes, and risk of adverse events (AEs).

Outcome measurements

The primary outcome was all-cause mortality, and the secondary outcomes were changes in FVC, diffusing capacity of the lung for carbon monoxide (DLCO), and the risk of AEs.

Quality assessment and data analysis

The Cochrane risk-of-bias tool was used to assess the quality and associated risks of bias of the included RCTs.[23] Two reviewers independently reviewed all of the included studies on the following items: randomization sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and inclusion of intention-to-treat analyses, and rated them as “low risk,” “high risk,” or “unclear risk”. If there was any disagreement, a third reviewer was consulted and a decision was reached by consensus.

Statistical analyses were performed using Review Manager (version 5.3; Nordic Cochrane Centre, Copenhagen, Denmark). Heterogeneity among the included studies was assessed using Cochran's Q test and \( I^2 \) statistic, and a p-value < 0.05 was considered to be statistically significant. When \( I^2 < 50\% \), a fixed effects model was used, otherwise a random effects model was used. Pooled odds ratios (ORs), mean differences (MDs) and 95% confidence intervals (CIs) were calculated for outcome analyses. Sensitivity analyses were performed to assess the contribution of each study by excluding one individual study and recalculating the pooled hazard ratio estimates for the remaining studies (leave-one-out meta-analysis).

Results

Study selection

The search results yielded a total of 1,374 studies from the online databases including PubMed (n = 27), Web of Science Core Collection (n = 24), Embase (n = 806), Cochrane Library (n = 24), clinicaltrials.gov (n = 4), and WHO International Clinical Trials Registry Platform (n = 6) (e-Table 1). Seventy-six studies were excluded as duplicates, 1,278 studies were found to be irrelevant after the title and abstract were screened, and 15 studies were excluded for having the same population, terminated (NCT01777737), no complete data
available (NCT00203697 and EUCTR2014-004058-32) and using a crossover design (NCT02173145) after the full text had been screened. Finally, four RCTs[12, 18, 20, 21] were included in this meta-analysis (Fig. 1).

**Study characteristics**

The characteristics of the four included RCTs are summarized in Table 1. Three studies[12, 18, 20] were double-blind and placebo-controlled design. Three RCTs[12, 18, 20] were conducted in the EU and one[21] was conducted in the US. Co-trimoxazole was the only studied antibiotic in three RCTs,[12, 18, 20] and one RCT[21] used co-trimoxazole or doxycycline as the experimental drug. The duration of additional antibiotic treatment varied among the four RCTs.[12, 18, 20, 21] Overall, a total of 1055 patients, including 528 who received additional antibiotics and 527 who received placebo or usual care were included in this meta-analysis. Among the study group, 402 and 126 patients were randomly assigned to receive co-trimoxazole or doxycycline, respectively.

| Study                | Design                                      | Study site       | Study period   | Study subjects                                                                 | Study drug                  | Control     | No. in study group | No. in control group | Primary outcome                        |
|----------------------|---------------------------------------------|------------------|----------------|--------------------------------------------------------------------------------|----------------------------|-------------|-------------------|----------------------|----------------------------------------|
| Varney et al, 2008[12] | Double-blind randomized placebo-controlled pilot study | Single center in the UK | NA             | Patients < 85 years old with progressive fibrotic lung disease                | co-trimoxazole for 3 months | Placebo     | 10                | 10                   | Exercise capacity                              |
| Shulgina et al, 2013[18] | Randomized placebo-controlled double-blind parallel-group | 28 sites in the UK | 2008–2009     | Patients aged > 40 years, with a diagnosis of fibrotic idiopathic interstitial pneumonia and a MRC dyspnea score of ≥ 2 | co-trimoxazole for 12 months | Placebo     | 95                | 86                   | Forced vital capacity                        |
| Wilson et al, 2020[20] | Double-blind placebo-controlled, parallel randomized trial | 43 sites in the UK | 2015–2019     | IPF diagnosed according to contemporaneous international guidelines and an mMRC dyspnea scale score > 1 | co-trimoxazole for between 12 and 42 months | Placebo     | 170               | 172                  | Time to all-cause death, lung transplant, or first non-elective hospital admission |
| Martinez et al, 2021[21] | Pragmatic, randomized, unblinded clinical trial | 35 sites in the US | 2017–2019     | Aged ≥ 40 years and diagnosed with IPF by the enrolling investigator           | co-trimoxazole or doxycycline + usual care | Usual care | 254               | 259                  | Time to first non-elective respiratory hospitalization or all-cause mortality |

IPF, idiopathic pulmonary fibrosis; mMRC, modified Medical Research Council; NA, not applicable

**Quality assessment**

There were risks of performance and detection bias due to the open labelled design in one study.[21] Another study did not describe the details of random sequence generation, and it only reported the outcome data of 123 of 181 randomized patients.[18] However, the author did perform imputation sensitivity analysis, which revealed that the results were robust even with the missing data. A summary of the risk of bias for the included studies[12, 18, 20, 21] is depicted in Fig. 2.

**Mortality**

Overall, the all-cause mortality rates were 15.0% (79/528) and 14.0% (74/527) among in the patients who did (study group) and did not (control group) receive additional antibiotics, respectively. As shown in Fig. 3, no significant difference was observed in mortality between the study and control groups (OR, 1.07; 95% CI, 0.76 to 1.51; p = 0.71; I² = 0%). The leave-one-out sensitivity analysis revealed that the magnitude of association between additional antibiotics with mortality was not influenced by individual studies.
Secondary outcomes

Compared to the control group, the use of additional antimicrobial agents was associated with mild improvements in FVC (MD, 0.01; 95% CI, -0.03 to 0.05; p = 0.56; \( I^2 = 0 \)) and DLCO (MD, 0.05; 95% CI, -0.17 to 0.28; p = 0.65; \( I^2 = 41 \% \)); however, these differences did not reach statistical significance (Fig. 4).

Adverse events

Compared to the control group, the use of additional antimicrobial agents was associated with an increased risk of AEs (OR, 1.65; 95% CI, 1.19–2.27; p = 0.002; \( I^2 = 18 \% \)) (Fig. 5). Among these AEs, there was a significant risk of gastrointestinal disorders (OR, 1.54; 95% CI, 1.10–2.15; p = 0.001; \( I^2 = 17 \% \)) and a trend of an increased risk of dermatological disorders (OR, 3.50; 95% CI, 0.81–15.06; p = 0.09; \( I^2 = 75 \% \)). There were no significant differences in hematological (OR, 1.47; 95% CI, 0.51–4.22; p = 0.47; \( I^2 = 0 \% \)) and renal (OR, 1.53; 95% CI, 0.67–3.46; p = 0.31; \( I^2 = 0 \% \)) disorders.

Discussion

In this meta-analysis, we reviewed four RCTs[12, 18, 20, 21] which compared the use of additional antimicrobial agents with placebo or usual care in terms of efficacy and safety for the treatment of adult patients with IPF. Our findings showed that antimicrobial agents (co-trimoxazole or doxycycline) did not provide additional benefits for patients with IPF in terms of mortality and FVC. In contrast, these agents were significantly associated with a higher risk of AEs, especially gastrointestinal toxicity. Based on these findings, the additional use of antimicrobial therapy for patients with IPF is not recommended.

Anti-fibrotic agents including pirfenidone and nintedanib have been approved and are widely used in several countries for the treatment of IPF. However, these two agents may not be available or affordable in certain countries. Immunomodulatory agents including azathioprine, colchicine, cyclophosphamide and interferon-gamma 1b have been investigated for the treatment of IPF, however, they have failed to show treatment benefits.[24] In addition, a recent meta-analysis also indicated that add-on anti-oxidative therapy with N-acetylcysteine to pirfenidone did not affect outcomes compared to pirfenidone alone.[25]

An earlier in vitro study showed that doxycycline could attenuate pulmonary fibrosis through the inhibition of growth factor and MMP production in alveolar epithelial cells.[13] Using a murine model, Kalemci et al demonstrated that the administration of minocycline may be effective in methotrexate-induced lung fibrosis.[14] In patients with IPF, Mishra et al showed that doxycycline therapy reduced the levels of MMP-9, MMP-3, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor in bronchial alveolar lavage fluid to near control values.[16] Previous studies have also demonstrated that the lung microbiome and bacterial burden can influence disease progression and outcomes in patients with IPF.[26, 27]

However, in the current meta-analysis, we found that the additional use of antimicrobial agents did not provide clinical benefits in patients with IPF. The reason for our negative findings could be multifactorial. First, our findings were based on the analysis of intention-to-treat populations, not per-protocol populations, and adherence to the study medications was poor in the included RCTs. In Shulgina's trial,[18] the adherence rate to the study medication (co-trimoxazole) was only 66.3% (63/95). In the EME-TIPAC trial of 169 patients randomized to receive co-trimoxazole,[20] 67 (39.6%) patients discontinued the medication and 26 (15.4%) reduced the dose. In the CleanUP-IPF trial,[21] adherence to the study medication at 12 months was only 47.2% among 163 patients, and only 49.5% of the study patients were followed up for more than 12 months. In addition, the findings of per-protocol analysis in Shulgina's study showed that co-trimoxazole was associated with a significant reduction in all-cause mortality (hazard ratio, 0.21; 95% CI, 0.06 to 0.78; p = 0.02) even though co-trimoxazole did not show a survival benefit based on the analysis of the intention-to-treat populations.[18]

Therefore, these findings raise the question of whether the insignificant effect of additional antimicrobial therapy could be due to poor adherence, and further studies with better adherence are warranted to solve this issue. Second, there was heterogeneity among the included RCTs, including the characteristics of each study population. The diagnostic criteria of IPF, severity of baseline lung function, underlying comorbidities, and treatment duration varied among these studies. Furthermore, anti-fibrotic agents were not available in two earlier studies,[12, 18] and more than 70% of the IPF patients received anti-fibrotic agents in the two most recent studies.[20, 21] Whether anti-fibrotic agents can influence the effect of anti-microbial agents is unknown. In addition, none of the included studies measured the number or type of lung microbes or the direct effect of antimicrobial agents on these microbiota, and therefore we cannot exclude the potential effect of antibiotics in selected patients with IPF and dysbiosis.
In terms of safety analysis, we found that the use of additional antimicrobial agents was significantly associated with a higher risk of AEs, especially gastrointestinal toxicity including diarrhea and vomiting, and a trend of dermatological side effects such as skin rash. These AEs were expected to be higher in the experimental group, however most were not fatal or serious. For other AEs, there were increased risks of hematological and renal disorders such as hyperkalemia and impaired renal function, although these differences did not reach statistical significance. However, the included patients in the trials were highly selected, and additional side effects associated with antimicrobial agents still need to be cautiously monitored in a clinical setting.

This meta-analysis had several limitations. First, the numbers of included studies and patients were relatively small, and adherence to the study medication was poor as mentioned above. Second, the antimicrobial agents were limited to co-trimoxazole or doxycycline, and the potential anti-bacterial benefits of co-trimoxazole may have been reduced due to widespread bacterial resistance. Other antibiotics such as macrolides and fluoroquinolones were not investigated in large studies. Third, we did not assess the effect of additional antimicrobial agents on other outcomes such as exercise tolerance with the six-minute walk test, risk of exacerbations or hospitalization, and quality of life because of a lack of data or differences in the measuring tools in different studies. However, the primary outcome in this meta-analysis demonstrated no significant difference in mortality in the patients who received additional antimicrobial agents, and this finding remained unchanged in leave-one-out sensitivity analysis, which could strengthen the results of this meta-analysis.

**Conclusion**

In conclusion, among patients with IPF, this meta-analysis indicated that adding antimicrobial therapy did not improve mortality or decline in lung function compared with placebo or usual care. In addition, these agents were significantly associated with a higher risk of AEs, especially gastrointestinal toxicity. These findings do not support the use of additional antimicrobial agents for improving the outcomes of patients with IPF.

**Abbreviations**

AE: adverse event; CI: confidence interval; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis; MD: mean difference; MMP: matrix metalloproteinase; OR: odds ratio; RCT, randomized control trial

**Declarations**

**Declarations and competing interests:**

All authors (C.-Y. Chen., C.-H. Chen, C.-Y. Wang, C.-C. Lai, C.-M. Chao, and Y.-F. Wei) have no conflicts of interest to disclose

**Funding:**

None

**Ethical approval and consent to participate:**

This article does not contain any studies with human participants or animals performed by any of the authors.

**Author Contributions:**

C.-Y. Chen., C.-H. Chen, C.-C. Lai, and Y.-F. Wei; methodology: C.-Y. Chen., C.-H. Chen, C.-C. Lai., and Y.-F. Wei; software: C.-Y. Chen, C.-H. Chen. C.-Y. Wang and C.-M. Chao; validation; C.-C. Lai, and C.-Y. Wang; formal analysis, C.-Y. Chen and C.-H. Chen; investigation: C.-Y. Wang, and C.-M. Chao.; resources and data curation: C.-Y. Chen, C.-H. Chen, and C.-Y. Wang; writing—original draft preparation, C.-Y. Chen. and C.-H. Chen; writing—review and editing: C.-Y. Wang, C.-C. Lai, and Y.-F. Wei; visualization: C.-Y. Wang, C.-M. Chao, C.-C. Lai and Y.-F. Wei; supervision: C.-Y. Wang, C.-C. Lai. and Y.-F. Wei

**Acknowledgements**

Not applicable
References

1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

2. Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, Wang JY, Chang YT, Chao TT, Lin HI, et al. Idiopathic pulmonary fibrosis in Taiwan - a population-based study. Respir Med. 2012;106:1566–74.

3. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;378:1811–23.

4. Yang SN, Perng DW, Ko HK, Chang YL, Hsu CC, Huang HY, Chung MI: Epidemiologic Analysis of Taiwanese Patients with Idiopathic Pulmonary Fibrosis. Healthcare (Basel) 2020, 8.

5. Navarretam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66:462–7.

6. Schäfer SC, Funke-Chambour M, Berezowska S. Idiopathic pulmonary fibrosis-epidemiology, causes, and clinical course. Pathologe. 2020;41:46–51.

7. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glasopole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.

8. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

9. Chen CH, Lin HC, Wang YH, Wang CY, Lin YS, Lai CC. The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2021;16:e0251636.

10. Sgalla G, Comes A, Richeldi L. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Expert Opin Drug Saf 2021;1–14.

11. Wright WA, Crowley LE, Parekh D, Crawshaw A, Dosanjh DP, Nightingale P, Thickett DR. Real-world retrospective observational study exploring the effectiveness and safety of antibiotics in idiopathic pulmonary fibrosis. BMJ Open Respir Res 2021, 8.

12. Varney VA, Parnell HM, Salisbury DT, Ratnathiepan S, Tayar RB. A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther. 2008;21:178–87.

13. Fujita H, Sakamoto N, Ishimatsu Y, Kakugawa T, Hara S, Hara A, Amenomori M, Ishimoto H, Nagata T, Mukae H, Kohno S. Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis. Respiration. 2011;81:420–30.

14. Kalemci S, Dirican N, Cetin ES, Sözen H, Uner AG, Yaylali A, Aksun S, Karacan V, Ulger E, Sütcü R, Dirican A. The efficacy of minocycline against methotrexate-induced pulmonary fibrosis in mice. Eur Rev Med Pharmacol Sci. 2013;17:3334–40.

15. Oda K, Yatera K, Fujino Y, Ishimoto H, Nakao H, Hanaka T, Ogoshi T, Kido T, Fushimi K, Matsuda S, Mukae H. Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan. BMC Pulm Med. 2016;16:91.

16. Mishra A, Bhattacharya P, Paul S, Paul R, Swarnakar S. An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. Lung India. 2011;28:174–9.

17. Bhattacharyya P, Nag S, Bardhan S, Acharya D, Paul R, Dey R, Ghosh M, Dey R, Saha I. The role of long-term doxycycline in patients of idiopathic pulmonary fibrosis: The results of an open prospective trial. Lung India. 2009;26:81–5.

18. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, Twentyman OP, Davison AG, Curtin JJ, Crawford MB, Wilson AM. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68:155–62.

19. Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoconomics. 2014;32:87–99.

20. Wilson AM, Clark AB, Cahn T, Chilvers ER, Fraser W, Hammond M, Livermore DM, Maher TM, Parfrey H, Swart AM, et al. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial. Jama. 2020;324:2282–91.

21. Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, et al. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUp-IPF Randomized Clinical Trial. Jama. 2021;325:1841–51.
22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103–12.

23. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.

24. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003:Cd003134.

25. Shi H, Yin D, Bonella F, Kreuter M, Oltmanns U, Li X, Peng S, Wei L. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med. 2020;20:128.

26. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, Martinez FJ. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2:548–56.

27. Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, Chua F, Wu Z, Wells AU, Renzoni ER, et al: Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. Eur Respir J 2020, 55.

**Figures**

![Flow diagram showing the identification of eligible trials and participating trials](image)
Figure 2

Summary of risks of bias in each domain for each included study

| Study or Subgroup       | antimalarial | placebo | Total | Weight | Odd's Ratio (M-H, Fixed, 95% CI) | Year |
|-------------------------|--------------|---------|-------|--------|----------------------------------|------|
| V.A. Varney et al. 2008 | 0            | 10      | 10    |        | Not estimable                    | 2008 |
| Shulgina L, et al. 2013 | 18           | 95      | 113   | 25.8%  | 0.82 [0.40, 1.70]                | 2013 |
| Andrew M. Wilson, et al. 2020 | 24       | 169     | 193   | 24.4%  | 1.42 [0.74, 2.72]                | 2020 |
| Fernando J. Martinez, et al. 2021 | 37     | 254     | 291   | 49.9%  | 1.02 [0.63, 1.67]                | 2021 |
| Total (95% CI)          | 528          | 527     | 1055  | 100.0% | 1.07 [0.76, 1.51]                |      |
| Total events            | 79           | 74      |       |        |                                  |      |

Heterogeneity: Chi² = 1.24, df = 2 (P = 0.54); I² = 0%
Test for overall effect: Z = 0.37 (P = 0.71)

Figure 3

Forest plot of the comparison of all-cause mortality between the study and control groups
Figure 4

Forest plot of the comparisons of FVC and DLCO between the study and control groups

Figure 5

Forest plot of adverse events between the study and control groups
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- PRISMA2009checklistWei.doc